BURLINGTON, ON, Sept. 27, 2012 /CNW/ - EKO is proud to announce that its JV partnership NeuroVasc Clinical Inc. has entered into an agreement with the prestigious Meyer Institute in Hamilton Ontario to provide FREMS to its family of patients. The Meyer Institute is one of Canada's leaders in the treatment and management of diabetic wounds and limb care. Dr Perry Meyer MD is an International lecturer on limb care and a proponent of research into new technologies to better serve patients and save limbs. FREMS provide an FDA and Health Canada approved clinic based treatment that acts to increase vascularity and nerve function in diabetic patients who suffer from neuropathy. Dr Paul Ziemer President of NeuroVasc Clinical has worked with the Meyer Institute in the past doing research into wound treatments. Neurovasc is in the process of completing the clinic installation which it anticipates will have 5 machines operating when fully completed with a capacity to treat 50 patients a day. Further news will be released as the clinic nears completion in the next month.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by Eko International ("The Company") are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
SOURCE: EKO INTERNATIONAL CORP.
For further information:
To contact the company by e-mail, please use [email protected]